risperidone 2 mg strides tablet
strides pharma (sa) (pty) ltd - tablet - see ingredients - each tablet contains risperidone 2,0 mg
metformin 1 000 strides tablet
strides pharma (sa) (pty) ltd - tablet - see ingredients - each tablet contains metformin hydrochloride 1000,0 mg
zodoray 1 ug capsules
strides pharma (sa) (pty) ltd - capsules - see ingredients - each capsule contains alfacalcidol 1,0 ug
zodoray 0,5 ug capsules
strides pharma (sa) (pty) ltd - capsules - see ingredients - each capsule contains alfacalcidol 0,5 ug
zodoray 0,25 ug capsules
strides pharma (sa) (pty) ltd - capsules - see ingredients - each capsule contains alfacalcidol 0,25 ug
calcilos 1 ug capsules
strides pharma (sa) (pty) ltd - capsules - see ingredients - each capsule contains alfacalcidol 1,0 ug
calcilos 0,5 ug capsules
strides pharma (sa) (pty) ltd - capsules - see ingredients - each capsule contains alfacalcidol 0,5 ug
calcilos 0,25 ug capsules
strides pharma (sa) (pty) ltd - capsules - see ingredients - each capsule contains alfacalcidol 0,25 ug
strides pyrazinamide tablets (pom)
pyrazinamide 400mg
nevirapine tablet
strides pharma science limited - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine 200 mg - nevirapine tablets, usp is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults and pediatric patients 15 days and older [see clinical studies (14.1, 14.2)] . limitations of use: based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine tablets, usp is not recommended to be initiated, unless the benefit outweighs the risk, in: - adult females with cd4+ cell counts greater than 250 cells/mm3 or - adult males with cd4+ cell counts greater than 400 cells/mm3 [see warnings and precautions (5.1)] . nevirapine tablets, usp are contraindicated: - in patients with moderate or severe (child-pugh class b or c, respectively) hepatic impairment [see warnings and precautions (5.1) and use in specific populations (8.7)] - for use as part of occupational and non-occupational post-exposure prophylaxis (pep) regimens [see warnings and precautions (5.1)] . pregnancy exposure registry th